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PDiabetes and Cardiovascular Disease
ngiotensin-Converting Enzyme
nhibitors or Angiotensin Receptor
lockers for Prevention of Type 2 Diabetes
Meta-Analysis of Randomized Clinical Trials
ussam Abuissa, MD, Philip G. Jones, MS, Steven P. Marso, MD, James H. O’Keefe, JR, MD
ansas City, Missouri
OBJECTIVES We sought to investigate the role of angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) in preventing the new onset of type 2 diabetes mellitus.
BACKGROUND Diabetes is a public health problem of epidemic proportions and its prevalence is on the rise.
The typical American born today has a one in three chance of developing type 2 diabetes.
This diagnosis is associated with an adverse cardiovascular prognosis and is considered the
risk equivalent of established coronary disease. Even in high-risk individuals, diabetes is a
preventable disease. Several studies have shown that ACE inhibitors and ARBs decrease the
incidence of new-onset type 2 diabetes. However, the exact role of these agents in diabetes
prevention has not yet been fully elucidated.
METHODS We conducted a meta-analysis of 12 randomized controlled clinical trials of ACE inhibitors
or ARBs, identified through a MEDLINE search and a review of reports from scientific
meetings, to study the efficacy of these medications in diabetes prevention.
RESULTS This showed that ACE inhibitors and ARBs were associated with reductions in the incidence
of newly diagnosed diabetes by 27% and 23%, respectively, and by 25% in the pooled analysis.
CONCLUSIONS The use of an ACE inhibitor or ARB should be considered in patients with pre-diabetic
conditions such as metabolic syndrome, hypertension, impaired fasting glucose, family history
of diabetes, obesity, congestive heart failure, or coronary heart disease. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.0512005;46:821–6) © 2005 by the American College of Cardiology Foundation
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more than 19 million adults in the U.S. and 150 million
dults worldwide have diabetes; by the year 2025, the World
ealth Organization projects more than 300 million cases
orldwide (1). The typical American born today has a one
n three chance of developing type 2 diabetes; for Hispanic
nd African American people, the risk is almost one in two.
or a man diagnosed with diabetes at age 40 years, the
verage life expectancy is reduced by approximately 11.6
ears and quality of life years by 18.6 (2). A diagnosis of type
diabetes carries such adverse prognostic implications
about 70% of diabetic patients die of cardiovascular disease)
hat it is considered the risk equivalent of established
oronary disease (3). Strategies to prevent type 2 diabetes
re, therefore, of paramount importance in improving the
ealth of the American population in the 21st century.
The recently characterized constellation of risk factors
eferred to as metabolic syndrome (due to underlying insulin
esistance) is a well-recognized precursor of type 2 diabetes
4). These patients are also at a high risk for cardiovascular
vents caused by accelerated atherosclerosis, hypercoagula-
ility, dyslipidemia, and endothelial dysfunction (4). Ap-
roximately 24% (47 million) of adult Americans have
etabolic syndrome. The prevalence of this disorder is
From the Mid America Heart Institute, Cardiovascular Consultants, Kansas City,
issouri.T
Manuscript received December 27, 2004; revised manuscript received April 28,
005, accepted May 10, 2005.ncreasing sharply and in parallel with the obesity epidemic
5,6).
Insulin resistance plays a causal role in hypertension and
therosclerosis, and thus is present to some degree in most
atients with these diseases. About 50% of hypertensive
ndividuals are hyperinsulinemic (7), and up to 75% of
eople with type 2 diabetes have hypertension (8). Abnor-
al glucose metabolism is seen in approximately two of
hree patients presenting with an acute coronary syndrome
with about equal numbers of patients having impaired
asting glucose and overt diabetes) (9).
In the milieu of insulin resistance, the cardiovascular
ystem is sensitized to the adverse trophic effects of the renin
ngiotensin aldosterone system (RAAS) (10,11), as evi-
enced by the frequent occurrence of diffuse arterial disease
nd left ventricular hypertrophy in diabetic patients, even
hen the lipid and blood pressure levels are normal. High
nsulin levels stimulate the angiotensin I receptor, which
ctivates the RAAS (12) and also increases cardiac sympa-
hetic nervous system function (13). Diabetic patients, in
articular, benefit from blockade of the RAAS, with reduc-
ion of cardiovascular mortality up to 40% in a major,
andomized, controlled trial (14).
Multiple large prospective trials have reported an unex-
ected reduction in the development of new type 2 diabetes
ellitus in patients treated with anti-hypertensive agents.
hese trials predominantly used angiotensin-converting
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ACE Inhibitors or ARBs for Diabetes Prevention September 6, 2005:821–6nzyme (ACE) inhibitors or angiotensin receptor blockers
ARBs) and have consistently shown reductions in the risk
f new diabetes ranging from 4% to 87% (Table 1).
To elucidate the role of ACE inhibitors and ARBs in
iabetes prevention, we conducted a meta-analysis of all
izable randomized clinical trials of ACE inhibitors or
RBs that reported data on the incidence of diabetes at
aseline and study end.
ETHODS
ata identification. We identified all randomized trials of
CE inhibitors or ARBs in which the incidence of new-
nset diabetes was reported. Candidate trials were sought
hrough a computerized bibliographic search of the
EDLINE database (National Library of Medicine, Be-
hesda, Maryland) for the period January 1990 to December
004, and were required to include randomization in their
esign. The ACE inhibitor and angiotensin blocker/
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
PPAR  peroxisome proliferator-activated receptor
RAAS  renin angiotensin aldosterone system
able 1. Prevention of Type 2 Diabetes by ACE Inhibitors or A
Trial
(Ref. No.)
No. of
Patients
Years of
Follow-Up*
APPP (15) 10,985 6.1 C
D
TOP-2 (16) 6,614 5 C
A
OPE (17) 9,297 5 R
Pl
IFE (18) 9,193 4.8 Lo
A
LLHAT (19) 33,357 4.9 Li
C
NBP2 (20) 6,083 Median 4.1 En
H
COPE (21) 4,937 3.7 C
Maximum 5 Pl
LPINE (22) 392 1 C
A
HARM (23) 7,599 3.2 C
Pl
OLVD (24) 4,228 3.4 En
Pl
ALUE (25) 15,245 4.2 V
A
EACE (26) 8,290 Maximum 7 T
Median 4.8 Pl
Mean years of follow-up or as indicated; †published risk ratios may have been der
ncidence ratios.
ACE  angiotensin-converting enzyme; ALLHAT  Antihypertensive and Li
reatment and Lipid Profile in a North of Sweden Efficacy Evaluation; ANBP2  T
APPP  Captopril Prevention Project; CHARM  Candesartan in Heart Failure
OPE  Heart Outcomes Prevention Evaluation; LIFE  Losartan Intervention
ngiotensin Converting Enzyme Inhibition Trial; SCOPE  The Study on Cognition a
TOP-2  The second Swedish Trial in Old Patients with hypertension; VALUE  Valntagonist classes were searched in subject headings, and
ndividual drug names were used as keywords. “(Diabetes or
ellitus or glucose or insulin)” within three words of “(new$
r emerg$ or prevent$ or develop$ or risk$)” were searched
n the title/abstract/subject heading. One hundred ninety-
ne articles were identified. The same search strategy was
sed to find citations in the Cochrane Database of System-
tic Reviews, ACP Journal Club, The Database of Abstracts
f Reviews of Effects, and Cochrane Central Register of
ontrolled Trials (Ovid Technologies Inc., New York, New
ork). One hundred two articles were identified with this
earch. The reference lists of all articles obtained were
xamined to identify additional trials. Abstracted studies
rom presentations at national meetings were included if
hey met the design criteria.
esearch selection. All titles and abstracts from the search
rocess were examined. Studies were retrieved if they met
he following criteria: 1) randomized comparison of an
CE inhibitor or an ARB to placebo or another anti-
ypertensive medication, 2) study duration of at least one
ear, 3) all study patients had a history of hypertension or at
east one cardiovascular risk factor, and 4) the incidence of
ew-onset diabetes during the study was reported in both
he treatment and the control groups (for those patients
ithout diabetes at baseline). We identified 13 published
ercent of New Diabetics
Risk Ratio
(95% Confidence Interval)†
ril 337/5,183 (6.5%) 0.79 (0.67–0.94)
/beta-blocker 380/5,230 (7.3%)
tional drugs 97/1,961 (4.9%) 0.96 (0.72–1.27)
hibitors 93/1,969 (4.7%)
il 102/2,837 (3.6%) 0.66 (0.51–0.85)
155/2,883 (5.4%)
n 241/4,019 (6%) 0.75 (0.63–0.88)
l 319/3,979 (8%)
ril 119/4,096 (8.1%) 0.70 (0.56–0.86)
alidone 302/6,766 (11.6%)
il 138/2,800 (4.9%) 0.66 (0.54–0.85)
200/2,826 (7.1%)
artan 93/2,167 (4.3%) 0.81 (0.61–1.02)
115/2,175 (5.3%)
artan  felodipine 1/196 (0.5%) 0.13 (0.03–0.99)
l  HCTZ 8/196 (4%)
artan 163/2,715 (6%) 0.78 (0.64–0.96)
202/2,721 (7%)
il 9/153 (5.9%) 0.26 (0.13–0.53)
31/138 (22.4%)
n 690/5,267 (13.1%) 0.77 (0.69–0.86)
pine 845/5,152 (16.4%)
lapril 335/3,432 (9.8%) 0.83 (0.72–0.96)
399/3,472 (11.5%)
om subgroup analyses and/or statistical models and do not necessarily equal crude
wering Treatment to Prevent Heart Attack Trial; ALPINE  Anti-hypertensive
ond Australian National Blood Pressure study; ARB  angiotensin receptor blocker;
essment of Reduction in Mortality and Morbidity; HCTZ  hydrocholorothiazide;
ndpoint Reduction in hypertension study; PEACE  Prevention of Events withRBs
P
aptop
iuretic
onven
CE in
amipr
acebo
sarta
tenolo
sinop
hlorth
alapr
CTZ
andes
acebo
andes
tenolo
andes
acebo
alapr
acebo
alsarta
mlodi
rando
acebo
ived fr
pid-Lo
he sec
—Ass
For End Prognosis in the Elderly; SOLVD  Studies Of Left Ventricular Dysfunction;
sartan Antihypertensive Long-term Use Evaluation.
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September 6, 2005:821–6 ACE Inhibitors or ARBs for Diabetes Preventiontudies of ACE inhibitors and ARBs (15–27). One study
27), however, was excluded because patients were not
andomized to receive an ACE inhibitor, which was only
sed as an add-on therapy for blood pressure control.
herefore, a total of 12 studies were used in our analysis.
ata analysis. Pooled risk ratios were calculated using
andom effects meta-analysis described by DerSimonian and
aird (28,29). Risk ratios and confidence intervals for a new
iagnosis of type 2 diabetes were obtained from published
ources for each of the 12 studies. Seven studies (15–
7,19,21,22,24) reported relative risks, four studies
18,20,23,26) reported hazard ratios, and one study (25)
eported an odds ratio. It was assumed that the hazard ratios
nd odds ratio were reasonable approximations of relative
isk. The 12 estimates and confidence intervals were log-
ransformed, and variances were calculated assuming Wald-
ype confidence intervals. A pooled estimate was then
alculated as a weighted average of the log-risk ratios, with
eights inversely related to the variances (i.e., estimates
rom studies with wide confidence intervals received less
eight than those with narrow intervals). Because of differ-
nces in the types of drugs used, study designs, and methods,
random effects model was chosen, which incorporates an
dditional factor in the weights to account for between-study
ariability. Heterogeneity of effects was confirmed by the
ochran test, p  0.008. The variance of the pooled estimate
as calculated as the inverse of the sum of the weights, and a
5% confidence interval was derived assuming normality.
inally, the pooled estimate and confidence limits were back-
ransformed to the original ratio scale. Pooled risk ratios were
alculated over all studies as well as separately for ACE
nhibitors and ARB studies. Analyses were performed using
igure 1. Pooled risk estimates of the different angiotensin-converting e
n Table 1. DM  diabetes mellitus; other abbreviations as in Table 1AS version 8.2 (SAS Institute Inc., Cary, North Carolina). iESULTS
f the 12 studies that met the criteria for entering the
eta-analysis, 7 used ACE inhibitors (15–17,19,20,24,26)
nd 5 used ARBs (18,21–23,25). These trials involved
16,220 patients, of whom 72,333 did not have diabetes at
aseline. Patients included in these studies had hypertension
r at least one other cardiovascular risk factor. Two of the
rials, namely Candesartan in Heart Failure-Assessment of
eduction in Mortality and Morbidity (CHARM) (23) and
tudies Of Left Ventricular Dysfunction (SOLVD) (24),
nvolved chronic heart failure patients, which is an insulin-
esistant state in which the development of diabetes is
articularly associated with increased morbidity and mor-
ality (30).
The ACE inhibitors and ARBs were compared with
lacebo, diuretics, beta-blockers, or calcium-channel antag-
nists. Although the incidence of new-onset diabetes was
efined differently among the trials, most used the Ameri-
an Diabetes Association criteria (31) of a fasting plasma
lucose of 126 mg/dl at two different visits in patients
ith no diabetes at the time of enrollment.
The mean duration of follow-up ranged from 1 to 6.1
ears. Reduction in the incidence of new-onset diabetes
anged from 4% to 87%. In two of the studies, namely the
econd Swedish Trial in Old Patients with hypertension
STOP-2) (16), and the Study on Cognition and Prognosis
n the Elderly (SCOPE) (21), this did not reach statistical
ignificance. Figure 1 shows pooled risk ratios of the
ifferent ACE inhibitor and ARB trials shown in Table 1.
he reductions in risk of new-onset diabetes were 27% for
CE inhibitors, 23% for ARBs, and 25% for either ACE
e (ACE) inhibitor and angiotensin receptor blocker (ARB) trials shownnhibitor or ARB (i.e., pooled over all studies).
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ACE Inhibitors or ARBs for Diabetes Prevention September 6, 2005:821–6ISCUSSION
ecent studies have suggested that ACE inhibitors and
RBs may play an important role in the prevention of type
diabetes; the current meta-analysis confirms such findings.
his meta-analysis, involving 72,333 non-diabetic patients
approximately 338,000 patient-years of follow-up), showed
hat ACE inhibitors or ARBs produced a highly significant
5% reduction (or a decrease from 17.4 to 14.3 cases per
,000 patient-years) in the incidence of new-onset diabetes.
his is especially important because many common cardio-
ascular conditions such as coronary disease, congestive
eart failure, and hypertension are associated with insulin
esistance and increased risk for the development of diabetes
7,8,32). Type 2 diabetes markedly worsens long-term
ardiovascular prognosis, and thus therapies to prevent this
isease are of great interest (33).
However, there are some limitations to these trials.
mportant among these is the fact that only 9 (17–19,21–
6) of the 12 trials were double-blind, whereas the other 3
15,16,20) used the prospective randomized open-blinded
nd point design. The definition of diabetes differed among
he trials. Only two trials, the Antihypertensive Treatment
nd Lipid Profile in a North of Sweden Efficacy Evaluation
ALPINE) (22) and the Antihypertensive Long-term Use
valuation (VALUE) (25), included the development of
iabetes as a pre-specified end point, whereas in the others,
his end point was a post-hoc analysis. The ALPINE study
howed a remarkable 87% reduction in the incidence of
ew-onset diabetes in the candesartan group as compared
ith the atenolol group. However, this study only included
92 patients and was of a short duration. On the other
and, the VALUE trial randomized a larger number of
atients, and follow-up was a mean of 4.2 years.
A similar proportion of patients in the both the valsartan
nd the amlodipine arms of the VALUE trial needed
djunctive diuretic and/or beta-blocker therapy for blood
ressure control, thus the highly significant 23% reduction
n new diabetes cases was not attributable to increased
nsulin resistance caused by other medications in the amlo-
ipine arm. The use of these adjunctive medications in some
atients assigned to ACE inhibitors or ARBs in the other
rials, however, may have affected the differences observed in
he emergence of new-onset diabetes between the treatment
roups, although the reduction of 23% in the VALUE trial
as identical to that achieved by ARBs in our meta-analysis.
The International Verapamil-Trandolapril Study
INVEST) investigators (27) reported that in 16,176 non-
iabetic, hypertensive patients with coronary artery disease,
he incidence of new diabetes cases was significantly lower
n the verapamil sustained-release/trandolapril strategy (7%)
ompared with the atenolol/hydrochlorothiazide strategy
8.2%) (relative risk, 0.85 [95% confidence interval, 0.77 to
.95]). Further analysis (34) of the results of this study
howed that the addition of 4 mg trandolapril to the
40-mg dose of verapamil significantly reduced the inci-ence of new-onset diabetes as compared with atenolol 50
g (hazard ratio, 0.58 [95% confidence interval, 0.44 to
.78]). However, trandolapril was an add-on therapy and
atients were not randomized to receive it, therefore, this
tudy was excluded from our meta-analysis.
The mechanisms of action whereby these medications
revent type 2 diabetes are speculative (24). The ACE
nhibitors not only block the conversion of angiotensin I to
ngiotensin II, but also increase bradykinin levels through
nhibition of kininase II-mediated degradation (35,36). In
ypertensive rats, Tomiyama et al. (37) have shown im-
roved insulin sensitivity with enalapril through an increase
n endogenous kinins. The higher kinin levels lead to an
ncreased production of prostaglandins (prostaglandin E1
nd prostaglandin E2) and nitric oxide, which improve
xercise-induced glucose metabolism (38) and muscle sen-
itivity to insulin (39–41), resulting in enhanced insulin-
ediated glucose uptake. Furthermore, the peripheral va-
odilatory actions of ACE inhibitors and ARBs lead to an
mprovement in skeletal muscle blood flow, the primary
arget for insulin action and an important determinant of
lucose uptake. This effectively increases the surface area for
lucose exchange between the vascular bed and skeletal
uscles. Clinical evidence supporting this effect has been
rovided by Morel et al. (42), who have demonstrated
mproved insulin sensitivity when enalapril was given for 12
eeks to 14 obese, hypertensive, and dyslipidemic patients.
similar effect has also been reported with captopril (43).
The protection against new-onset diabetes may in part be
elated to adipocyte function. Mature adipocytes are inte-
rally involved with the RAAS. Investigators have theorized
hat increased levels of angiotensin II inhibit pre-adipocyte
ifferentiation into mature adipocytes, and this impairs the
at cells’ ability to store fat. This in turn results in shunting
f fats to the liver, skeletal muscle, and pancreas, which
orsens insulin resistance. Reducing angiotensin II levels
ith an ACE inhibitor or blocking the angiotensin II
eceptor with an ARB may promote differentiation of
re-adipocytes to mature adipocytes, which serve as a sump
or fat. Additionally, redistribution of the lipids from the
eripheral tissues would improve insulin sensitivity (44).
Another theory relates to a possible protective effect of
RBs and ACE inhibitors on the pancreatic beta cell
hrough inhibiting the vasoconstrictive effect of angiotensin
I in the pancreas and increasing islet blood flow (45), which
ould improve insulin release by beta cells. Telmisartan, an
RB, has been shown to act as a peroxisome proliferator-
ctivated receptor (PPAR)-gamma agonist, similar to the
hiazolidinediones rosiglitazone and pioglitazone, which
reserve pancreatic beta-cell function (46). These experi-
ental and clinical studies suggest that blocking the effects
f angiotensin II (through ACE inhibition or receptor
lockade) increases insulin sensitivity, skeletal muscle glu-
ose transport, and pancreatic blood flow, which may
ontribute to the prevention of diabetes mellitus.Therefore, an ACE inhibitor or ARB is a logical first-line
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September 6, 2005:821–6 ACE Inhibitors or ARBs for Diabetes Preventionnti-hypertensive agent in patients with impaired fasting
lucose or metabolic syndrome for multiple reasons, includ-
ng the reduction in risk of progression to overt type 2
iabetes. Even in patients without diabetes or metabolic
yndrome, what was previously thought to be a “high-
ormal” blood pressure (120/80 to 139/89 mm Hg) is
ssociated with an increased risk of adverse cardiovascular
vents (47). In fact, this blood pressure range is now
onsidered “pre-hypertension” per new Joint National
ommittee 7 guidelines (48). Some of the most widely used
nti-hypertensives, particularly the traditional beta-blockers
uch as metoprolol and atenolol and diuretics (in high
oses) such as hydrochlorothiazide and chlorthalidone,
orsen insulin sensitivity and increase risk of new-onset
ype 2 diabetes (19). However, carvedilol, an alpha-beta
locker with antioxidant properties, has been shown to have
eutral effects or to slightly improve rather than worsen
nsulin sensitivity (49).
Angiotensin-converting enzyme inhibitors and ARBs not
nly lower blood pressure but also may possess unique
ardioprotective properties (10). They improve endothelial
unction and regress both left ventricular hypertrophy and
rterial mass better than other anti-hypertensive agents that
ower blood pressure equally as well (10). They also reduce
ates of death, myocardial infarction, stroke, cardiac arrest, and
evascularization procedures (10). Angiotensin-converting en-
yme inhibitors have been shown to protect against oxidative
tress and prevent glycosylation of proteins, which may
onfer cardiovascular benefit (50). These agents are gener-
lly well tolerated, especially the ARBs, which have a side
ffect profile similar to placebo. Thus, in patients with
onditions associated with insulin resistance, such as meta-
olic syndrome, hypertension, impaired fasting glucose,
amily history of diabetes, obesity, congestive heart failure,
r other risks for the development of type 2 diabetes, the use
f an ACE inhibitor or ARB should be considered.
Additional trials will be needed to confirm the role of
CE inhibitors and ARBs in diabetes prevention, and no
harmacologic agent is currently approved for this particular
ndication. Prospective trials that specifically address this
ssue are underway, including the Diabetes REduction
pproaches with ramipril and rosiglitazone Medications
DREAM) trial with the ACE inhibitor ramipril and the
ateglinide And Valsartan in Impaired Glucose Tolerance
utcomes Research (NAVIGATOR) trial with the ARB
alsartan. Finally, the ONgoing Telmisartan Alone and in
ombination with Ramipril Global Endpoint Trial
ONTARGET) will also investigate as a secondary end
oint whether it is possible to prevent the development of
ype 2 diabetes by blocking the RAAS with either an ACE
nhibitor or an ARB or a combination of both. Using the
ame outcomes, the Telmisartan Randomized AssessmeNt
tudy in aCE iNtolerant patients with cardiovascular Dis-
ase (TRANSCEND) compares telmisartan with placebo
or individuals who are unable to take ACE inhibitors
ecause of intolerable side effects.eprint requests and correspondence: Dr. Hussam Abuissa, Mid
merica Heart Institute, Cardiovascular Consultants, 4330
ornall Road, Suite 2000, Kansas City, Missouri 64111. E-mail:
buissah@umkc.edu.
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